IO9
DEAD

Serial Number

97677741

Owner

io9, LLC

Attorney

John L. Slafsky

Filing Date

Nov 15, 2022

Add to watchlist:

No watchlists yet
View on USPTO

IO9 Trademark

Serial Number: 97677741

IO9 is a trademark filed by io9, LLC on November 15, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

io9, LLC (3 trademarks)

8540 Avenida de las Ondas
La Jolla, CA 92037

Entity Type: 16

Trademark Details

Filing Date

November 15, 2022

Registration Date

Not Registered

Published for Opposition

October 17, 2023

Goods & Services

Downloadable computer software for detecting and treating cancer using artificial intelligence (AI)

Biological and chemical preparations for the prevention and treatment of cancer; Pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors; Medical reagents; Diagnostic kits comprised of medical diagnostic reagents, assays for testing of bodily fluids for use in disease detection, namely, cancer; stem cells, protein arrays, and molecular compounds for medical purposes; Pharmaceutical preparations for use in oncology; Antitumor drugs in the nature of pharmaceutical preparations

Medical services for the treatment and detection of cancer; Medical analysis services using artificial intelligence (AI) for the diagnosis of cancer; Providing cancer screening services; Providing a website via a global computer network featuring information in the fields of health, cancer, cancer treatment, recovery and survival, and artificial intelligence use in medicine; RNA or DNA analysis for cancer diagnosis and prognosis

Software as a service (saas) services featuring software for detecting and treating cancer using artificial intelligence (AI); Development of pharmaceutical preparations and medicines; Drug discovery services; Medical research in the field of cancer; Pharmaceutical research and development services; Research and development of pharmaceuticals for the treatment of cancer; medical and scientific research, namely, conducting clinical trials for others; DNA screening and analysis services for scientific research purposes

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jul 14, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jul 14, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2025 EXRA
SOU EXTENSION 2 GRANTED
Dec 2, 2024 EX2G
SOU EXTENSION 2 FILED
Dec 2, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Dec 2, 2024 EEXT
SOU EXTENSION 1 GRANTED
Jun 11, 2024 EX1G
SOU EXTENSION 1 FILED
Jun 11, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 11, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 12, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 17, 2023 NPUB
PUBLISHED FOR OPPOSITION
Oct 17, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 27, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 12, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 12, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 12, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 12, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 12, 2023 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 7, 2023 GNRN
NON-FINAL ACTION E-MAILED
Sep 7, 2023 GNRT
NON-FINAL ACTION WRITTEN
Sep 7, 2023 CNRT
ASSIGNED TO EXAMINER
Aug 29, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 6, 2022 NWOS
NEW APPLICATION ENTERED
Nov 18, 2022 NWAP